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Background: Preliminary reports led to discordant conclusions concerning the use of con-
trast-enhanced intraoperative ultrasonography (CE-IOUS) during surgery for colorectal liver
metastases (CLM). The aim of this study was to evaluate the impact of CE-IOUS in patients
undergoing surgery for CLM using an advanced preoperative imaging work-up, and well-
established reference standards.
Materials and methods: Forty-seven consecutive patients underwent liver resection using
IOUS and CE-IOUS for CLM. All patients underwent preoperative computed tomography
(CT) and magnetic resonance imaging (MRI) within 2 weeks prior to surgery. CE-IOUS
was performed by injecting intravenously 4.8 ml of sulphur-hexafluoride microbubbles
(SonoVue, Bracco, Italy). Reference standards were histology, and 6-month imaging
follow-up.
Results: IOUS discovered 43 additional lesions in 20 patients. CE-IOUS found 10 additional
lesions not seen at IOUS in four patients, and confirmed all the IOUS findings. Fourteen
CLM in 10 patients appeared within 6 months after surgery. Sensitivity, specificity, positive
predictive value, negative predictive value and accuracy were, respectively: 66%, 0%, 98%,
0% and 65% for CT + MRI; 88%, 100%, 100%, 8%, 88% for IOUS and 93%, 100%, 100%, 13%,
93% for IOUS + CE-IOUS. In nine patients CE-IOUS afforded better definition of tumour
margins thus helping in resection guidance.
Conclusions: CE-IOUS improves IOUS findings both for detection and for resection guidance.
The combination of IOUS and CE-IOUS should be considered routinely in patients operated
for CLM.
 2008 Elsevier Ltd. All rights reserved.er Ltd. All rights reserved.
grant from Bracco International BV.
3; fax: +39 02 8224 4590.
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1. Introduction
Intraoperative ultrasonography (IOUS) is still the most accu-
rate diagnostic technique for detecting focal liver lesions
(FLLs).1,2 However, during surgery for colorectal liver metasta-
ses (CLM), IOUS shows a sensitivity of only 82%,3 and there-
fore may miss nodules less than 1 cm in diameter. This is
particularly evident in patients who undergo surgery after
chemotherapy in whom CLM have a similar echo-pattern to
the surrounding liver parenchyma. For this reason contrast-
enhanced intraoperative ultrasonography (CE-IOUS) was pro-
posed in 2004 both for CLM and for HCC detection,4 but
the preliminary results, although encouraging for HCC5,6,
remained inconclusive for CLM.7–9 In particular, Fioole et al.
recently concluded that CE-IOUS does not appear to be neces-
sary in CLM surgery since it does not significantly improve the
accuracy provided by preoperative computed tomography
(CT) and IOUS.9 However, in these studies, the criteria for esti-
mating the diagnostic accuracy of CE-IOUS were lacking.
Indeed, CE-IOUS findings were compared with a suboptimal
preoperative diagnostic work-up based either on CT alone9
or with CT and magnetic resonance imaging (MRI) used
non-homogeneously.7,8 In view of these drawbacks and of
the very preliminary experiences with CE-IOUS, we were
prompted to perform a more extensive analysis to assess
the actual role of CE-IOUS in CLM surgery.2. Method
2.1. Definitions
The reference standard for establishing sensitivity, specificity,
accuracy, and positive and negative predictive values of pre-
operative imaging, IOUS and CE-IOUS were histology of the
removed specimens and postoperative follow-up imaging.
Any new metastasis detected within the first 6 months of fol-
low-up was considered as a lesion not seen at preoperative
(CT/MRI) nor at intraoperative imaging (IOUS and CE-IOUS).
A bright liver on IOUS was defined when liver–kidney con-
trast was evident, and the blurring of the intrahepatic vessels
and the diaphragm both related to the diffusely increased
liver echogenicity.10
2.2. Preoperative work-up
The preoperative imaging work-up consisted of an abdominal
ultrasound (US), abdominal MRI and CT and chest spiral CT.
CTand MRI were always performedwithin 2 weeks of surgery.
A tri-phase CT examination was performed using a Philips
Mx 8000 IDT 16multidetector CT scanner, andmore recently a
Philips Brillance 64 using the following settings: 16 · 1.5 colli-
mation, 2 mm thickness, 1 mm increment and 1.2 pitch for
the first scan, and 64 · 0.25 collimation, 2 mm thickness,
1 mm increment and 0.7 pitch for the second. CT enhance-
ment was obtained using an iodinated contrast agent (Iomer-
on 300, Bracco SpA, Milan, Italy) injected in a peripheral vein
at 3–5 ml/s. Contrast-enhanced arterial phase, portal-venous
phase and late phase were evaluated following the bolus
injection at 25–30 s, 45–65 s and 120 s, respectively.MRI was routinely performedwith two different 1.5 T mag-
Simphony, Erlangen, Germany) with phase array coils. A
liver-specific MR contrast agent (MultiHance, Bracco SpA, Mi-
lan, Italy) at a standard dose of 1 ml/kg was used; pre-contrast
axial and coronal T2- and T1-weighted 2D sequenceswere first
performed. A dynamic, axial, 3D enhanced studywas then car-
ried out at 17, 45 and 120 s, and at 60 min following a bolus
injection of the contrast agent in a peripheral vein at 2 ml/s.
Patients were selected for surgery on a technical feasibility
regardless of the size or number of metastases, at a multidis-
ciplinary meeting.
2.3. IOUS and CE-IOUS
A J-shaped laparotomy was usually performed. After entering
the abdominal cavity, liver mobilisation was achieved by dis-
secting the round and falciform ligaments. Division of adhe-
sions was carried out as necessary to free the antero-
superior and inferior surfaces of the liver before liver explora-
tion with IOUS.
IOUS was performed using an Aloka SDD 5500 (Aloka Ltd.,
Tokyo, Japan) equipped with the standard 3–6 MHz convex
probe, and the 7.5–10 MHz micro convex probe. Staging was
completed by CE-IOUS using the standard convex probework-
ing at 3–6 MHz frequency for B-mode and at 1.88–3.76 MHz
harmonic frequency. In all patients, 2.4 ml of sulphur-hexa-
fluoride microbubbles (SonoVue, Bracco, Milan, Italy) was in-
jected through a peripheral vein by the anaesthetist.
Ultrasound guidance was used to drive the dissection
plane as previously described.2
All the IOUS and CE-IOUS assessments were carried out by
the same surgeon (GT) who carried out also the hepatecto-
mies. Informed consent was obtained from all patients but
no approval was required by the Ethics Review Board of the
hospitals involved in this clinical study because the contrast
agent used is licensed for liver imaging in our country.
2.4. Inclusion criteria
The study included consecutively enrolled patients with CLM
who underwent surgery and during this procedure received
IOUS and CE-IOUS.
To be included in the study each patient had at least 6
months of postoperative follow-up.
Patients who after IOUS and CE-IOUS had explorative lap-
arotomy only were excluded from the analysis since there
was no histological confirmation of the tumour and most of
them were lost to surgical follow-up.
2.5. Patient follow-up
The patients were followed up in our institution every 3
months by an expert hepatobiliary team who performed
physical examination, liver function tests, serum carcino-
embryonic antigen (CEA), US (twice a year) and CT/MRI (twice
a year). At the 6-month follow-up each patient underwent CT/
MRI unless the US examination at 3 months after surgery dis-
covered a new lesion, in which case CT/MRI was performed
earlier.
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The study end-points were
• Overall sensitivity, specificity, positive and negative predic-
tive values (PPV and NPV, respectively), and accuracy of
IOUS alone and IOUS with CE-IOUS compared with findings
of preoperative imaging.2.7. Statistical analysis
Two-tailed Student t test was used to compare continuous
variables.
Sensitivity, specificity, PPV, NPV and accuracy were calcu-
lated for preoperative diagnostic imaging, IOUS and CE-IOUS
based on results at histology and evidence of new liver lesions
within the first 6 months of follow-up.
Chi squared test was used for comparing sensitivity, spec-
ificity, PPV and NPV amongst preoperative imaging, IOUS and
IOUS + CE-IOUS.
The P value was set at 0.05.
2.8. Patients
Between May 2005 and September 2007, 53 patients under-
went a laparotomy following a diagnosis of CLM. Six patients
(13%) were excluded from the analysis because they had an
explorative laparotomy only due to peritoneal carcinomatosis
(three patients), or lymph node metastasis (three patients).
Forty-seven consecutive patients – 34 males and 13 females,
mean age of patients was 64.4 years (median 66.5 years; range
36–85 years) – underwent liver resection using IOUS and CE-
IOUS. The imaging diagnostic workup for all the enrolled pa-
tients included abdominal US followed by contrast-enhanced
CT and MRI; five patients also received contrast-enhanced
ultrasonography (CEUS), and three patients received fine-nee-Fig. 1 – (a) This illustration shows a colorectal cancer liver meta
IOUS since it was located adjacent to the portal branches to seg
(b) at CE-IOUS the lesion (arrow) appearing as a black hole is wdle biopsy. The last 42 patients also had 18-FDG-PET. All CT
and MRI scans were carried out within 2 weeks prior to the
operation.
Median number of days from 18-FDG-PET to surgery was
20 (mean 26; range 3–90). Ten of the 47 patients had diffuse
steatosis of the liver, four patients had cirrhosis, one patient
had chronic hepatitis, and the remaining 32 patients had nor-
mal livers; all patients with liver steatosis had undergone pre-
vious systemic chemotherapy. The total number of tumours
at preoperative imaging was 129 (median two per patient;
mean 2.7 per patient; range 1–9 per patient), with a mean
diameter of 3.2 cm (median 3; range 1–8) for the largest tu-
mour. Thirty-one patients (66%) had multiple metastases at
preoperative imaging. In the last 42 patients 18-FDG-PET dis-
closed globally 85 lesions (median two per patient; mean 2.8
per patient; range 1–9 per patient) compared to the 116 dis-
covered by CT and MRI (median two per patient; mean 2.8
per patient; range 1–9 per patient).3. Results
3.1. Detection
At IOUS, 170 lesions were detected (mean per patient 3.6;
median 3; range 1–11) 43 of which were new lesions in 20 pa-
tients (43%) as compared to preoperative imaging. Moreover,
IOUS ruled out a preoperative diagnosis of metastasis for
two nodules in two patients. CE-IOUS discovered 10 addi-
tional CLM lesions not seen on IOUS in four patients (9%)
(Fig. 1), amongst whom one patient had no additional sites
on IOUS. Overall, IOUS and CE-IOUS disclosed 180 lesions
(mean per patient 3.8, median 3, range 1–13), 53 of which were
new lesions not detected at preoperative imaging in 21 pa-
tients (45%). The two lesions preoperatively diagnosed as
metastases, but not confirmed by IOUS were also not visual-stasis (arrow) which was difficult to recognise after
ments 6 and 7 (P6-7) and to segments 5 and 8 (P5-8);
ell evident. RHV = right hepatic vein.
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IOUS and CE-IOUS.
After IOUS and CE-IOUS, 35 patients (74%) were found to
have multiple CLM. All the new lesions at IOUS and CE-IOUS
were detected in the patients who underwent surgery for
multiple CLM (mean per patient 3; median 3.8; range 1–9) at
preoperative imaging, in all but three cases (90%). The mean
number of preoperative lesions in this subgroup of patients
was significantly higher than in the remaining patient popu-
lation (3.8 versus 2; P = 0.003).
The diameter of the lesions detected only by CE-IOUS ran-
ged from 0.3 to 1.1 cm.
Four new lesions on IOUS and none on CE-IOUS were de-
tected in the five patients who were found to have a bright li-
ver according to the aforementioned definition (Fig. 3).Fig. 2 – Flow-chart shows the additional findings of IOUS and c
(CE-IOUS) and their output in terms of modified surgery.
Fig. 3 – (a) The lesion (T) in a bright liver is visible since the con
contribution provided by CE-IOUS in this case is less dramatic tLimiting the analysis to the last 42 patients who under-
went also 18-FDG-PET in their preoperative work-up, IOUS
and CE-IOUS disclosed globally 167 lesions (median 3 per
patient; mean 4 per patient; range 1–13 per patient). In par-
ticular, 9 of the 10 new lesions detected only by CE-IOUS
were found only in this subgroup of patients. Noticeably,
there were three patients with no liver lesions at PET scan,
but CT + MRI and IOUS + CE-IOUS found four, three and one
lesion, respectively: all these patients received chemother-
apy prior to preoperative staging and surgery. Additionally,
18-FDG-PET disclosed less lesions than CT + MRI in other
15 patients, and less than IOUS + CE-IOUS in other 22 pa-
tients. 18-FDG-PET disclosed more lesions than CT + MRI
in three patients which were all confirmed at IOUS + CE-
IOUS.ontrast-enhanced intraoperative ultrasonography
trast with the surrounding parenchyma is clear; (b) the
han in that shown in Fig. 1.
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CE-IOUS allowed better visualisation of the tumour margins
of the main lesions in nine of the 47 patients (19%) which in
turn enabled a better definition of the resection area, and of
the liver dissection plane, resulting in easier resection guid-
ance (Fig. 4).
3.3. Surgical outcome
All 53 new liver lesions detected at IOUS and CE-IOUS in 21
patients were resected along with the 127 lesions diagnosed
preoperatively as CLM and intraoperatively confirmed by
IOUS and CE-IOUS. The distribution of the lesions was bilobar
in 21 patients, limited to the right hemi-liver in 20 patients,
and to the left hemi-liver in six patients. Major resection
(P3 segments) was performed in two patients (4%). For 18
(86%) of the 21 patients with new lesions at IOUS and CE-IOUS
the surgical approach was modified to include a limited resec-
tion. Amongst them were three of the four patients with new
CLM at CE-IOUS. Fig. 2 summarises the findings provided by
IOUS and CE-IOUS and their operative consequences.
At histology all the removed nodules were confirmed as
metastases.
After a mean follow-up of 16 months (median 14
months; range 6–34 months), 27 (57%) patients had recur-
rent disease: in 19 (40%) the liver was involved. The mean
disease-free survival time was 13 months (median 9; range
1–34) and the mean hepatic-free survival was 13 months
(median 11; range 1–34); five (11%) patients died during the
follow-up. Ten patients (21%) developed 14 new liver lesions
in another segment within 6 months after operation (mean
2.8; median 2; range 1–4); all these nodules were less thanFig. 4 – (a) The margins of the lesion invading the right hepatic
(IVC) are unclear at IOUS; (b) at CE-IOUS the lesion (T) becomes
the RHV and the IVC. MHV = middle hepatic vein.2 cm in diameter at the time of detection, and were consid-
ered as metastases not seen at preoperative (CT/MRI) and
intraoperative (IOUS and CE-IOUS) imaging. Of these, five
patients with six new CLM at follow-up had additional ad-
verse factors at the time of surgery, such as lymph node
metastases in four and major vascular invasion in one pa-
tient who had 10 lesions removed. Another four patients
(9%) had new CLM within 12 months after surgery (8, 8, 9
and 12 months, respectively). All these CLM were less than
2 cm in diameter. Of the two patients with the FLLs diag-
nosed preoperatively as metastases but not confirmed by
IOUS and CE-IOUS and therefore not removed, one is alive
at 24 months after surgery, but with lung and hepatic recur-
rence 17 months after resection, and one had a new lesion 2
months after surgery and died 17 months after the opera-
tion. None of the new lesions detected postoperatively were
at the site ruled out by IOUS and CE-IOUS.
Table 1 shows sensitivity, specificity, PPV, NPV, and accu-
racy of preoperative imaging, IOUS and IOUS + CE-IOUS in
detecting CLM. Preoperative imaging had significantly lower
sensitivity, specificity and NPV than IOUS and IOUS + CE-
IOUS (P < 0.05). PPV did not reach significance for any of
the comparisons. The sensitivity, specificity, PPV and NPV
were not significantly different for IOUS and IOUS + CE-
IOUS.
3.4. Adverse reactions and costs
No clinically evident adverse reactions were reported during
and after the intravenous injection of the contrast agent.
Additional costs to the surgical procedure due to CE-IOUS,
assuming the use of one sample of contrast agent per patient,
were 61.36 euros/patient.vein (RHV) at its confluence into the inferior vena cava
clearly visible by its margins and its relation with
Table 1 – Sensitivity, specificity, positive and negative predictive values and accuracy of preoperative imaging, IOUS and
contrast-enhanced intraoperative ultrasonography (CE-IOUS) in carriers of CRC liver metastases
Preoperative imaging
(CT + MRI)
IOUS IOUS + CE-IOUS
Sensitivity 66 88 93
Specificity 0 100 100
Positive predictive value 98 100 100
Negative predictive value 0 8 13
Accuracy 65 88 93
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Complete surgical clearance of multiple CLM even in the pres-
ence of vascular infiltration is justified since, significant ben-
efits in term of long-term survival are reported.11 Tumour
staging by IOUS does not appear totally adequate.3 We have
previously shown that CE-IOUS is able to improve IOUS sensi-
tivity since it allows recognition of new CLM in 21% of pa-
tients, resulting in a reduced risk of down-staging, and an
enhanced rate of treatment with curative intent.7 These re-
sults were partially confirmed by multicentre, and, more re-
cently monocentre experience.8,9 However, the conclusions
were not homogeneous. Leen et al. considered CE-IOUS a use-
ful addition to IOUS, Fioole et al. concluded the opposite,
although results apparently were not that different. All these
studies were based on preliminary experiences in small num-
bers of patients with CE-IOUS, and moreover with different
criteria for patients enrolment and data analysis. Reference
standards were different amongst the series, and therefore
the comparability of results was reduced, thus lowering the
impact once a summary analysis was attempted.
It is important to establish how CE-IOUS should be consid-
ered, either as a new autonomous diagnostic tool, or as part of
the IOUS procedure to be integrated with the findings of the
unenhanced phase. In our opinion the latter should be con-
sidered more appropriate, since CE-IOUS is performed by
the same operator immediately after IOUS, which undoubt-
edly guides CE-IOUS scanning. Indeed, CE-IOUS scans can
be focused on other liver portions knowing what IOUS has
demonstrated. On the other hand when establishing accu-
racy, CTand MRI are also considered independently, including
both the unenhanced and enhanced phases.
The experience herein reported comes from work started
in 2002. However, for this study only the most recent series
was considered, thus excluding those patients who were part
of the previously reported analysis.7 Nevertheless, the 47
consecutive patients enrolled represent the largest reported
series of CE-IOUS for CLM in a monocentric setting. An impor-
tant point that differentiates this study from previous reports
is the fact that all the patients underwent abdominal CT and
MRI prior to surgery. All previous reports had heterogeneous
preoperative diagnostic work-up with 66–100% of patients
having only a CT exam.7–9 In addition, in the previously re-
ported studies preoperative examinations were carried out
2–6 weeks prior to surgery, i.e. a time interval which is too
long to rule out the risk of possible development of new tiny
lesions. In the present series all the patients were operated
within 2 weeks of the preoperative imaging.A further strength of this study is that, to establish the va-
lue of IOUS and CE-IOUS in improving intrahepatic staging
and as consequence surgical radicality, not only histology
was considered, but also the imaging follow-up. Indeed, accu-
racy, sensitivity, specificity, PPV and NPV were analysed based
also on follow-up findings, which make this series different
from those previously reported in which findings at follow-
up were not considered8 or were considered as a whole with-
out time limit. Thus no attempt to differentiate between the
new CLM which were missed at IOUS and CE-IOUS and those
that developed postoperatively was made.9 Six months of
postoperative follow-up were considered adequate for dis-
criminating the CLM missed during surgery from those that
developed subsequently. Synchronous metastases are those
lesions which appear within the 6 months after surgery12;
conversely, in our series 9% of patients had new CLM from 6
to 12 months after surgery, and all of them after 8 months.
Furthermore, all lesions detected intraoperatively in this ser-
ies were removed and histological confirmation was obtained
whilst in previous reports a significant proportion of patients
received intraoperative thermal ablation of the new sites.8,9 In
the series of Leen et al. all patients who received ablation
therapy underwent previous intraoperative fine needle biopsy
(FNB), which was not the case in the series reported by Fioole
et al. in which diagnostic confirmation was obtained only as
follow-up findings for those who received ablation therapy:
this method of evaluation may lead to inaccurate
conclusions.9
Despite the more meticulous preoperative diagnostic
imaging performed in our series using latest generation CT
and MRI, IOUS and CE-IOUS impacted on the intrahepatic
staging and the surgical approach by providing new findings
in 55% of patients, with a significantly higher sensitivity,
specificity and NPV than CT and MRI combined. Although,
the two lesions detected at CT and MRI and properly uncon-
firmed at IOUS and CE-IOUS accounted for the shocking dis-
crepancy amongst the respective specificities (Table 1),
anyway, globally, these results support the message that IOUS
and CE-IOUS should still be performed in spite of the ad-
vanced preoperative imaging. Certainly, the higher rate of pa-
tients with multiple CLM (74%) who underwent surgery in our
series compared to the others, may explain the significance of
the findings obtained with IOUS combined or not with CE-
IOUS, and those at preoperative imaging: indeed, multiple
CLM lesions are generally associated with a higher rate of
missed lesions at preoperative imaging.13 As further confir-
mation of that, 90% of patients with new CLM at IOUS
and CE-IOUS received surgery for multiple metastases at
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number of lesions detected preoperatively than the others.
The high rate of patients with multiple lesions who under-
went surgery together with the precise reference standard
based on histology and follow-up could also explain the rela-
tively high rate of patients with early recurrence (21%) despite
the impact of IOUS and CE-IOUS findings.
Curiously, limiting the analysis to a subgroup of patients
who had also PET scan prior to surgery, it appears that this
diagnostic and staging modality is not that accurate when
per liver lesion comparisons were made with CT and MRI,
and consequently with IOUS and CE-IOUS. Furthermore, PET
scan proved to be inadequate for those patients who had prior
chemotherapy. Although, these data were retrospectively re-
viewed, they are in line with most of the prospective studies
confirming that PET scan is particularly useful for extra-hepa-
tic staging.14–16
Once it has been shown that IOUS and CE-IOUS provide
significant additions to the findings of CT and MRI com-
bined and also of PET scan by adopting precise reference
standard methods, the non-significant difference between
findings of IOUS and IOUS + CE-IOUS should be discussed.
Indeed, this result could lead to CE-IOUS which is consid-
ered a useless additional modality, as concluded by Fioole
et al.9 However, based on these estimations the role of IOUS
should be reconsidered too, since most of the findings in all
series were obtained in patients with multiple CLM at pre-
operative imaging. Therefore, IOUS should be recommended
only for selected patients; i.e. those who have multiple CLM.
However, some concerns arise with this approach. Indeed,
in this and all the previously published reports, CE-IOUS
constantly provided new findings: in particular in this series
CE-IOUS identified 10 lesions undiscovered by IOUS alone,
and that in spite of the advanced preoperative imaging
adopted. Although not significant, this is the confirmation
that CE-IOUS adds something to IOUS in all the series
examined and therefore, its routine use should be recom-
mended. On the other hand, unenhanced CT, although pro-
viding less information than the enhanced modality, and
additional irradiation, is still routinely performed since it
adds some information.17 A further series, based on a larger
number of patients and on a strict protocol of reference
standard, will probably consolidate the value of CE-IOUS,
and help to better clarify its impact from a statistical point
of view. Conversely, in our opinion there is already enough
evidence for judging unethical a randomised trial comparing
two groups undergoing surgery for CLM with IOUS alone
and with IOUS and CE-IOUS together.
The only condition in which, in our opinion, the use of CE-
IOUS could be reconsidered and eventually not performed is
in the presence of bright liver at IOUS: indeed, in all these pa-
tients in whom the contrast between lesion and surrounding
parenchyma was evident at IOUS, CE-IOUS did not add any
new findings (Fig. 3). On the other hand, Leen et al. reported
that CE-IOUS was not carried out in a patient with bright liver
showing more than 10 CLM at IOUS.8 However, the definition
of bright liver could be biased by the operator’s judgement,
and there is not enough evidence to make a definitive conclu-
sion, but there are reasons for supporting further evaluations
of the real utility of CE-IOUS in these patients.Enhancing the contrast between the tumour and the sur-
rounding parenchyma has another advantage other than im-
proved detectability, i.e. a better definition of the tumour
margins and of the relationship with adjacent vascular struc-
tures7 as in the example in Fig. 4. This situation provided by
CE-IOUS was confirmed in 19% of our patients, and Leen
et al. described a patient in whom CE-IOUS helped in defining
tumour margins.8 This additional information obtained with
CE-IOUS was more evident in the present series, and in the
one we previously reported,7 than in those which have fol-
lowed.8,9 This is possibly due to the fact that this is a subjec-
tive finding and that in our series CE-IOUS was always carried
out by the surgeon himself. Therefore the combination of
ultrasound findings and surgical requirements could have en-
hanced the value of this additional information. Indeed, a bet-
ter definition of tumour margins helps the surgeon to define
the resection margin, which becomes crucial if the surgical
team adopts a conservative approach to maximise the spar-
ing of liver parenchyma by getting closer to the tumour mar-
gin under ultrasound guidance. Surgical policy, as we have
repeatedly shown, provides benefit in terms of safety of the
surgical treatment, technical feasibility of the resection itself
and long-term survivals.18–21 This surgical policy accounts for
the high rate of modified operations based on IOUS and CE-
IOUS findings.
All the patients we studied underwent CE-IOUS using a
convex lower frequency echo-probe different from the other
authors who used intraoperative high-frequency probes.
Although, small and stable intraoperative probes are more
suitable for surgical exploration especially when the liver is
not yet well mobilised, lower frequency probes, as those used
for CEUS, despite the lower resolution power than the higher
frequency one, allow longer and stronger contrast enhance-
ment. The longer time of exploration, the stronger enhance-
ment which is obtained and the lower frequency itself all
contribute to better exploration of the deeper portions of
the liver, providing for, a better panoramic view than that ob-
tained with higher frequency probes. Possibly in the future,
the development of dedicated technology for CE-IOUS will al-
low a proper compromise between the different features
needed for an optimal exploration. In our opinion, IOUS
and, consequently CE-IOUS, are useful methods not only to
establish the staging of the disease but also to guide the sur-
gical manoeuvres. Accordingly it is crucial that they are per-
formed by the surgeon himself to exploit all their potential
and maximise their impact.
Some authors have raised concerns on the safety of CE-
IOUS.22 However, Piscaglia et al. have recently shown on a
large multicentric series23 how the rate of severe adverse
events is really minimal (0.0086%). Furthermore, the intraop-
erative use of this technique is expected to be even at lower
risk for any adverse event since it is restricted to patients
undergoing advanced surgery performed under constant
anaesthesiological control24. Indeed, in the present series no
adverse events were clinically recorded during and after the
administration of the contrast agent.
A further concern could be the additional costs provided
by CE-IOUS. Considering that the end-point of CE-IOUS is
the improvement in the detection power of occult CLM, and
for this purpose it works, we believe that an additional cost
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the results herein and elsewhere reported.
In conclusion, this study confirms in an homogeneously
analysed prospective and monocentric series that IOUS sensi-
tivity is enhanced by CE-IOUS in patients with CLM. The tech-
nique is safe and provides additional information despite
advanced preoperative imaging and a meticulous IOUS. Fur-
thermore, although subjective, CE-IOUS provides additional
findings in a relevant portion of patients to assist in recognis-
ing the dissection plane since it defines the tumour margins
more precisely. For all these reasons, CE-IOUS should be rec-
ommended routinely in patients with CLM; its use in the pres-
ence of a bright liver at IOUS remains to be better determined.
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